Cabozantinib (Cabometyx) demonstrated impressive progression free survival (PFS) when administered post-immunotherapy in patients with metastatic renal cell carcinoma (RCC), according to findings from a retrospective real-world study.1
All-grade adverse events were reported in 83 patients (74%), with grade 3-4 adverse events reported by 39 (35%).
- Santini D, Stellato M, De Giorgi U, et al. Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): a Meet-URO group real-world study (Meet-Uro 7). Presented at: GU Cancers Symposium; February 13-15, 2020; San Francisco, CA. Abstract 691.
- Graham J, Shah AY, Wells JC, et al. Outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy after immuno-oncology checkpoint inhibitors.[published online ahead of print, 2019 Nov 27]. Eur Urol Oncol. 2019;S2588-9311(19)30160-9. doi:10.1016/j.euo.2019.11.001.
... to read the full story